People who live with narcolepsy — about one out of every 2,000 Americans — don’t have many options when it comes to treatment. The milder form of narcolepsy includes symptoms of excessive ...

Findings published in Brain Sciences showed missed doses and potential for injury when waking to take a second dose among the key challenges ...

By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, e-commerce, Drug Stores and Others) & Region for 2024 to ...

Axsome's AXS-12 reduces narcolepsy symptoms, positioning the company for success. Find out why AXSM stock is a buy with ...

NEWARK, Del, Nov. 27, 2024 (GLOBE NEWSWIRE) -- The Narcolepsy Treatment Market 2024 to 2034 is expected to experience substantial growth, with the market size projected to expand from USD 5,301.6 ...

mezagitamab, an investigational anti-CD38 antibody providing rapid, selective and sustained depletion of disease-causing ...

(MENAFN- GlobeNewsWire - Nasdaq) Narcolepsy treatment market by Product (Narcolepsy Treatment Drugs and Devices), By Distribution channel (Hospital Pharmacies, Retail Pharmacies, e-commerce ...

Centessa's pipeline is anchored by two main drug candidates: ORX750 for narcolepsy and SerpinPC for hemophilia B. These innovative treatments are positioned to potentially disrupt their respective ...

Axsome Therapeutics (NASDAQ:AXSM) said a long-term Phase 3 study of its drug AXS-12 for the treatment of narcolepsy with ...